ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

IMNN Imunon Inc

1.4947
-0.0153 (-1.01%)
최종 업데이트: 23:18:04
15분 지연
기업명 주식 심볼 시장 주식 타입
Imunon Inc IMNN 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
-0.0153 -1.01% 1.4947 23:18:04
개장가 저가 고가 종가 전일 종가
1.52 1.46 1.52 1.51
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
08/05/202421:15EDGAR2Form 8-K - Current report
08/05/202421:00GLOBEIMUNON Appoints Director Dr. Stacy R. Lindborg as President..
07/05/202400:00GLOBEIMUNON to Hold First Quarter 2024 Financial Results and..
18/04/202421:30GLOBEIMUNON’s IND Application Cleared to Begin Human Testing of..
11/04/202421:00GLOBEIMUNON Reports Compliance with Nasdaq Listing Requirements
28/03/202421:00GLOBEIMUNON Reports 2023 Financial Results and Provides Business..
25/03/202421:30GLOBEIMUNON Receives $1.3 Million from Sale of its New Jersey Net..
22/03/202406:00GLOBEIMUNON to Hold 2023 Financial Results and Business Update..
13/03/202421:00GLOBEIMUNON Files IND Application to Begin Human Testing of..
13/03/202406:00GLOBEIMUNON Announces Leadership Change
29/02/202422:30GLOBEIndependent Lab Confirms Immunogenicity and Protection with..
27/02/202422:30GLOBEMemorial Sloan Kettering Cancer Center Now Enrolling..
22/02/202422:00GLOBEIMNN-101 Preclinical Data in SARS CoV-2 Published in..
10/02/202406:09EDGAR2Form S-1/A - General form for registration of securities..
30/12/202306:30EDGAR2Form 8-K - Current report
21/12/202307:15EDGAR2Form S-1 - General form for registration of securities under..
12/12/202306:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202306:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/12/202322:35EDGAR2Form 8-K - Current report
11/12/202322:30GLOBEIMUNON Appoints Dr. Sebastien Hazard as Chief Medical..
14/11/202323:00GLOBEIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14/11/202322:00GLOBEIMUNON Reports Third Quarter 2023 Financial Results and..
07/11/202322:30GLOBEIMUNON to Hold Third Quarter 2023 Financial Results and..
23/10/202321:30GLOBEIMUNON’s Chief Science Officer to Present at the 3rd..
19/10/202321:30GLOBEIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel..
18/10/202321:30GLOBEIMUNON Announces First Patient enrolled in Phase 1/2..
06/10/202321:30GLOBEIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory..
28/09/202321:30GLOBEIMUNON Reports Interim Progression-Free Survival and Overall..
26/09/202321:30GLOBEIMUNON Releases Enterprise Video Highlighting the Company’s..
13/09/202321:30GLOBEIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at..
08/09/202305:30GLOBEIMUNON to Host Virtual R&D Day on September 14th Beginning..
05/09/202321:30GLOBEIMUNON to Participate in the H.C. Wainwright Global..
25/08/202305:05GLOBEIMUNON Enters into CRADA for Preclinical Studies of PlaCCine..
14/08/202321:30GLOBEIMUNON Expands Scientific Advisory Board with the Addition..
10/08/202321:00GLOBEIMUNON Reports Second Quarter 2023 Financial Results and..
07/08/202321:30GLOBEPreclinical Data Showing Strong Immunogenicity and..
03/08/202321:30GLOBEIMUNON to Hold Second Quarter 2023 Financial Results and..
28/06/202301:00GLOBEIMUNON Unveils New Manufacturing Capabilities at..
27/06/202306:00GLOBEImunon Reports Inducement Grants under NASDQ Listing Rule..
12/06/202321:30GLOBEIMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy..
08/06/202321:30GLOBEIMUNON’s CEO Presents Business Overview to Investors and..
30/05/202321:00GLOBEIMUNON Presents PlaCCine Preclinical Data at the 2023..
11/05/202321:00GLOBEIMUNON Reports First Quarter 2023 Financial Results and..

최근 히스토리

Delayed Upgrade Clock